Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 2232 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

Table of Contents   
Year : 2011  |  Volume : 22  |  Issue : 1  |  Page : 158-159
Author's Reply

Consultant Nephrologist, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Preston, United Kingdom

Click here for correspondence address and email

Date of Web Publication30-Dec-2010

How to cite this article:
Ahmed A. Author's Reply. Saudi J Kidney Dis Transpl 2011;22:158-9

How to cite this URL:
Ahmed A. Author's Reply. Saudi J Kidney Dis Transpl [serial online] 2011 [cited 2021 May 17];22:158-9. Available from: https://www.sjkdt.org/text.asp?2011/22/1/158/74372
To the Editor,

I have read with confusion the letter sent to you commenting on my paper. Clearly, the author/authors of this letter did not read my paper that was published in your journal care­fully. He is criticizing things that are not there. I regret to say that I do not accept these com­ments and I think that it is a waste of our and your time going through that letter.

There was no mention in my review that 59 mL/min/1.73 m2 eGFR is the cut-off value that differentiates out age-related from pathological decline in GFR.

It is well known that there are limitations of the MDRD equation in the estimation of GFR, and one of its limitations is that it is not accu­rate when GFR is near to normal; hence, most of the Labs in the UK report eGFR when it is the range of CKD 1 and 2 as >60 mL/min. The KDOQI classifies the CKD stages 1 and 2 with a must of other evidence of kidney damage.

I am surprised by the comment saying that we "overlooked the repeated finding of losing the association between cardiovascular disease (CVD) and GFR decline among CKD3 pa­tients in the absence of microalbuminuria''. We have clearly stated that in the Prevention of Renal and Vascular End Stage Disease (PREVEND) study, patients with macroalbu­minuria, defined as ≥300 mg albumin/24 H urine, showed a -7.2 mL/min/1.73 m2 GFR loss compared with -2.3 mL/min/1.73 m 2 in the control group (P < 0.001). [1]

We have also stressed that in the MRFIT study, the risk of developing a renal event was 12-folds in patients with CKD stage 1 with microalbuminuria as compared with patients with no CKD (95% CI, 10.3-23.9). The risk was only 2.4-folds in CKD stage 3 patients without micoalbuminuria (95% CI, 1.5-3.8), which increased to 41-folds in CKD stage 3 patients with microalbuminuria (95% CI, 15.2- 71.1). [2] Thus, clearly, our review was not read and was just criticized!

We also clearly quoted a large study from the United States of 27,998 patients with GFR <90 mL/min/1.73 m2 followed-up for 5 years, where the rate of renal replacement therapy initiation was 1.1%, 1.3% and 19.9%, respectively, for CKD stages 2, 3 and 4. The average age in that study was above 61 years for all the stages. [3]

Again, we were right in quoting that 1.2% (38 out of the 3069) of the people with CKD in the Norwegian prospective study progressed to ESRD. [4] I am not sure from where the authors of this letter brought the 0.1% figure.

Regarding the rest of the letter, I do not want to comment on many parts that are not related to my paper, especially when the author is mentioning his own practice. Clearly, our prac­tices are so different as are our interpretations of clear facts in the literature and misreading numbers in the published data.

Finally, I would like to take the chance to thank you for the time you have given to our paper and I hope that we will collaborate in the near future with more manuscripts.

   References Top

1.Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006;17:2582-90.  Back to cited text no. 1
2.Ishani A, Grandits GA, Grimm RH, et al. Asso­ciation of single measurements of dipstick pro­teinuria, estimated glomerular filtration rate, and haematocrit with 25-year incidence of end stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006;17: 1444-52.  Back to cited text no. 2
3.Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63.  Back to cited text no. 3
4.Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross section­nal health survey. Br Med J 2006;333:1047-53.  Back to cited text no. 4

Correspondence Address:
Aimun Ahmed
Consultant Nephrologist, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Preston
United Kingdom
Login to access the Email id

Rights and Permissions


    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded165    
    Comments [Add]    

Recommend this journal